Skip to main content

Can Psilocybin Treat OCD?

A new study that was authored and published in the Journal of Psychedelic Studies by Eddie Jacobs, a neuroethicist, suggests that psilocybin exhibits great potential as a treatment for obsessive compulsive disorder (“OCD”). Jacobs, who is from the University of Oxford and King’s College London, admits that the inadequacy of studies that research the therapeutic potential of psilocybin in the treatment of OCD is surprising.

Psilocybin is a psychedelic compound that is found in magic mushrooms. In the recent past, the FDA granted psilocybin breakthrough status designation for its use as an alternative therapy for major depressive disorder and treatment-resistant depression. Breakthrough therapy status simply means that the clinical evidence is clinically meaningful and supported with results that promise better outcomes than existing interventions. Apart from helping manage depression, psilocybin therapy…

Read More >>

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.